Evidence map›Paper›PMID 39416174›Full record

ArticlebioRxiv : the preprint server for biology2024

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma.

Nai-Yun Sun, Suresh Kumar, Yoo Sun Kim, Diana Varghese, Arnulfo Mendoza, Rosa Nguyen, Reona Okada, Karlyne Reilly, Brigitte Widemann, Yves Pommier and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Nai-Yun SunDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Suresh KumarDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Yoo Sun KimDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Diana VargheseDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Arnulfo MendozaPediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Rosa NguyenPediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Reona OkadaPediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Karlyne ReillyPediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Brigitte WidemannPediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Yves PommierDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Fathi ElloumiDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Anjali DhallDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Mayank PatelLaboratory of Pathology, Center for Cancer Research, NCI, Bethesda, MD, USA.
Etan AberPediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Cristie Contreras-BurrolaPediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Rosie KaplanPediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Dan MartinezDepartment of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jennifer PogorilerDepartment of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Amber K HamiltonDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, and Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Sharon J DiskinDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, and Children's Hospital of Philadelphia, Philadelphia, PA, USA.
John M MarisDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, and Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-8088-7929
Robert W RobeyLaboratory of Cell Biology, Center for Cancer Research, NCI, Bethesda, MD, USA.
Michael M GottesmanLaboratory of Cell Biology, Center for Cancer Research, NCI, Bethesda, MD, USA.
Jaydira Del RiveroDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
Nitin RoperDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.

Funding

Elucidating the role of the noncoding genome in neuroblastomaR01CA237562 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI DISKIN, SHARON · 2021 to 2025
$2.0M
NCI NIH HHS R01 CA237562
6 · The paper itself

Abstract

Immunotherapeutic targeting of cell surface proteins is an increasingly effective cancer therapy. However, given the limited number of current targets, the identification of new surface proteins, particularly those with biological importance, is critical. Here, we uncover delta-like non-canonical Notch ligand 1 (DLK1) as a cell surface protein with limited normal tissue expression and high expression in multiple refractory adult metastatic cancers including small cell lung cancer (SCLC) and adrenocortical carcinoma (ACC), a rare cancer with few effective therapies. In ACC, ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC), shows potent

Identifiers

PMID39416174
PMCPMC11482787

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.